Moore Capital Management LP raised its holdings in shares of Sanofi (NASDAQ:SNY – Free Report) by 458.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 275,060 shares of the company’s stock after buying an additional 225,779 shares during the quarter. Moore Capital Management LP’s holdings in Sanofi were worth $13,329,000 as of its most recent SEC filing.
A number of other large investors have also modified their holdings of SNY. Raymond James Financial Inc. grew its holdings in shares of Sanofi by 81.3% during the second quarter. Raymond James Financial Inc. now owns 5,879,894 shares of the company’s stock worth $284,058,000 after buying an additional 2,635,867 shares in the last quarter. Capital Research Global Investors purchased a new stake in shares of Sanofi in the fourth quarter valued at about $79,960,000. Morgan Stanley grew its holdings in shares of Sanofi by 20.4% in the fourth quarter. Morgan Stanley now owns 9,102,196 shares of the company’s stock valued at $441,093,000 after purchasing an additional 1,540,271 shares during the period. Franklin Resources Inc. grew its holdings in shares of Sanofi by 29.7% in the fourth quarter. Franklin Resources Inc. now owns 5,100,097 shares of the company’s stock valued at $247,151,000 after purchasing an additional 1,168,339 shares during the period. Finally, BNP Paribas Financial Markets grew its holdings in shares of Sanofi by 422.1% in the third quarter. BNP Paribas Financial Markets now owns 1,062,809 shares of the company’s stock valued at $50,165,000 after purchasing an additional 859,246 shares during the period. Hedge funds and other institutional investors own 14.03% of the company’s stock.
Sanofi Trading Down 3.5%
Shares of SNY stock opened at $42.50 on Thursday. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.01 and a quick ratio of 0.22. The firm has a market cap of $103.04 billion, a PE ratio of 11.87, a price-to-earnings-growth ratio of 1.09 and a beta of 0.34. The company has a 50-day moving average of $44.88 and a two-hundred day moving average of $46.39. Sanofi has a 1-year low of $42.28 and a 1-year high of $52.68.
Sanofi Increases Dividend
Wall Street Analyst Weigh In
A number of equities research analysts recently issued reports on SNY shares. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a report on Thursday, March 19th. Morgan Stanley set a $52.00 price objective on shares of Sanofi in a report on Friday, May 1st. Wall Street Zen lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. BNP Paribas Exane lowered shares of Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price objective for the company. in a report on Monday, April 20th. Finally, Weiss Ratings raised shares of Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, May 13th. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and ten have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $51.00.
Get Our Latest Stock Analysis on Sanofi
Sanofi Profile
Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.
Key commercial offerings include specialty biologics and established small-molecule medicines.
See Also
- Five stocks we like better than Sanofi
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.
